Not a urologist but I study urology: prostate cancer screening, biopsy, treatment & harm reduction. Also dabble in regulatory affairs. Opinions are my own.
American Express: "This call will be monitored and recorded for quality assurance and training purposes."
Me: "Ok, in that case I will also record the call."
American Express: "Ok in that case if you are recording the call, we cannot proceed."
🙄
🚨 LIVE from AUA – @marcojruro is presenting metanalysis of BPH treatment.Congrats to this outstanding urology candidate-soon to be Research Fellow in Cincinnati and future Urology Resident! Proud to support the next generation of innovators. #AUA2026#Urology#BPH#Endourology
Any KM curve showing biopsy results from AS or focal therapy should include, on the same graph a freedom from biopsy KM curve! It’s hard to interpret without knowing the denominator. #eau26#prostatecancer
@jimhumd These options all seem heavy handed in light of ProtecT. There are a few certainties w/ PCa. One is that
favourable intermediate rest disease can absolutely safely be watch for a year. Watch it - change your treatment decision basis being a photograph to a movie!
Aquablation demonstrated noninferior short-term LUTS relief and similar safety compared to LEP, with superior ejaculation preservation and avoidance of SUI in short-term follow-up. #BPH#Aquablation#menshealth https://t.co/0Ki1g2OlbL
FDA is now open to Bayesian statistical approaches. A leap forward!
Bayesian statistics can help:
✅ Clinical trial design
✅ Finding the optimal dose
✅ Extrapolation to children
✅ Leveraging phase 2 results in phase 3
Dr. Inderbir Gill, @USC_Urology discusses how the WATER IV Prostate Cancer trial came about - which compares #Aquablation to Radical Prostatectomy. @PROCEPTRobotics https://t.co/ooflH0eluh
@DrRishabhOnco I disagree that ProtecT is a low-risk study. A third of the patients were intermediate risk at diagnosis, but it was before MRI. If you diagnosed the ProtecT population today with MRI guided biopsy half would be intermediate-risk.
@DrRishabhOnco I disagree that ProtecT is a low-risk study. A third of the patients were intermediate risk at diagnosis, but it was before MRI. If you diagnosed the ProtecT population today with MRI guided biopsy half would be intermediate-risk.